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Research objective: Morphological study of tissue necrosis stages in experimental organ-
preserving tuberculosis pharmacotherapy using Quercetin and Polyvinylpyrrolidone (QP).
Background and methods: 32 laboratory mice of C57BL/6JLacSto strain were used in the
experiment. The animals were divided into five groups, six to seven mice in each: group
1- Mycobacterium tuberculosis (MBT) uninfected mice; group 2- MBT infected mice; group
3- MBT infected and treated with antituberculosis preparation (ATP); group 4- MBT infected
and QP treated; group 5- MBT infected and treated with ATP and QP. The mice were infected
through caudal vein injection with MTB H37Rv strain. The preparation QP, which belongs to
the capillary-stabilizing-remedy group, was used for the research. The ATP were izoniazid
and streptomycin.
Results: QP produced a strict delineation of caseous necrosis from the unaffected parts of
the connective tissue with fibrosis in the center and a large number of Langerhans cells,
which was not observed in the control groups without QP. The combination of QP and
ATP had more pronounced effects. In MBT-infected mice, where QP was not used, unlike
the group where QP was used, adipose dystrophy of hepatocytes was observed. Thus, the
hepatoprotective effect of QP against TB can be suggested.
Conclusion: QP produces a clear delineation of caseous necrosis from an uninfected tissue
by connective-tissue formation, and by forming fibrotic tissue in the center of epithelioid
cells that prevents further TB dissemination by enhancing TB pharmacotherapy.
 2015 Asian African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.humanity [2]. Therefore, in April 1993, the World Health
Introduction
In recent years in Ukraine, as in many countries, we observed
an unstable epidemiological situation connected withtuberculosis (TB) [1], which became a silent social threat to
Organization (WHO) recognized the fact that TB is a global
threat [3]. In addition, TB is the leading disease among alln Avenue,
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according to the estimations conducted by theWHO, 9.0 million
people were infected with TB, and of those 1.5 million died [1].
The results of treatment of patients suffering fromdestruc-
tive pulmonary TBwith bacterio excretion in spite of high pos-
sibilities of antibacterial therapy remain insufficient [4–6].
Antimycobacterial therapy regimes recommended by the
WHO allow achieving negative smear in 67–96.3% of patients
suffering from TB [7–9]. One of the factors that increases the
treatment efficiency of patients with pulmonary TB is the
development of new treatment technologies [4,10,11]. Accord-
ing to most authors, themainmodernmethod of treatment of
TB is connected with the integrated approach to the use of
antibacterial drugs [12–15]; their use now is urgently needed.
Thus, the problem of treatment of patients with destructive
pulmonary TB is very topical and difficult.
One reason for the ineffective treatment of TB patients is
the insufficient modern view concerning pathomorphism
and pathophysiological interacting processes of the macroor-
ganism with Mycobacterium tuberculosis (MBT), which dictates
the need for the implementation of an integrated effect
method into the medical process not only to suppress MBT,
but also to preserve lung tissue from further destruction.
Organ preservation from the consequences of TB
influences a patient’s future life. With the progression of the
tuberculous process and myocardial hypoxia, which occurs
as a result of the destruction of lung tissue, cardiopulmonary
insufficiency develops, from which the patient dies. The
restoration of respiratory function in the case of pulmonary
TB is an important criterion for clinical treatment, and for
the medical and social rehabilitation of patients with respira-
tory diseases. The aforementioned effects may be obtained by
applying an effective treatment.
In each form of TB, immunopathological inflammation
caused by the violation of microcirculation and trophic fac-
tors of lung tissue occurs, which may be complicated by its
melting, secreting of cheesy masses through the bronchi,
and the formation of cavities (i.e., the process transition in
the destructive form). This worsens the course of TB, result-
ing in the subsequent loss of a part of or even the whole
organ, unless an adequate, effective type of therapy is
applied. According to some authors, there is a necessity for
a new effective integrated treatment in the therapeutic condi-
tions [16–18]. According to the literature, treatment schedules
primarily aim at the destruction of MBT. We have not seen
works connected with the application of therapy of organ
preservation by limiting the spread of the pathological pro-
cess, preventing lung-tissue melting and the rapid decline
of intoxication syndrome with the restoration of the
immune-system functioning. We focused our attention on
quercetin with polyvinylpyrrolidone (QP). QP is a chemical
compound that is used in clinical practice for the treatment
of patients suffering from myocardial infarction. However,
in the literature, there is no information on the use of QP in
the case of TB. QP is a chemical compound that belongs to a
group of capillary-stabilizing drugs and antioxidants
(bioflavonoids). The main effect of QP in the treatment of
myocardial infarction is the separation of necrosis tissue from
healthy areas. Thus, the spreading of necrosis to healthy
areas is halted and localization of the pathological processin the affected organ is observed, which leads to its preserva-
tion. The attempt to find out the morphological changes that
would confirm the separation of caseous necrosis convinced
us to initiate the study on the effectiveness of QP against TB
in mice, as a property of the drug consists not only of the
effect on ‘‘sterile” necrosis, but perhaps also on inflammation
in the infectious disease process.
Materials and methods
Thirty-two laboratory mice of C57BL/6J strain were used in
the experiment. The experimental study of QP was conducted
according to the literature [19], which provided an example of
research of pharmacological compounds in the case of TB in
mice.
The mice (17 males and 15 females) were all young (males:
3 months, 12 ± 5 days; females: 3 months, 26 ± 5 days). The
weight of the female mice varied from 18.17 g to 19.83 g
(18.83 ± 0.52 g), whereas that of the male mice varied from
19.35 g to 20.47 g (19.8 ± 0.38 g). None of the animals have
been used in any previous research. All animals were kept
under the same housing and feeding conditions.
The mice were infected via caudal-vein injection with MBT
H37Rv strain [19]—0.5 mL of isotonic solution (according to
group), which corresponds to 2.0  107 microbial bodies of
the laboratory strain of MBT H37Rv.
The animals were divided into five groups, with six to
seven mice in each group: (a) Group 1, MBT-uninfected mice;
(b) Group 2, MBT-infected mice; (c) Group 3, MBT infected and
treated with anti-TB preparation (ATP); (d) Group 4, MBT
infected and treated with QP; and (e) Group 5, MBT infected
and treated with ATP and QP. The ATP included isoniazid
and streptomycin.
Recalculation of the doses of the drugs used (QP, isoniazid,
and streptomycin) for the mice was carried out using the con-
version factor of doses between a person and a mouse, which
is generally accepted in conducting research [20]. Thus, the
drug doses for the mice contained the following: isoniazid
(10%, 5 mL), 45 mg/kg; streptomycin (1 g), 90 mg/kg; and QP
(0.5 g), 45 mg/kg of the body weight of a mouse. The
medicines used in the experiment on the mice were applied
as follows: isoniazid and streptomycin, intramuscularly once
a day; and QP, intraperitoneally according to a schedule
(on the 5th day after the introduction of the infection every
2 h, and then every 12 h; on the 6th day and 7th day two times
a day every 12 h).
Based on the literature [19], treatment was performed on
the 5th day after the animals had been infected and after
pathomorphological (macroscopic and microscopic) confir-
mation of the presence of the TB process in the mice.
Mouse removal was conducted using chloroform overdose
on the 11th day after the introduction of MBT [21].
The lungs, spleens, and livers of the control and experi-
mental groups of animals were used for the morphological
examination.
The degree of lesions on the internal organs of the mice
and comparisons depending on the character of the given
treatment were evaluated macroscopically [22] by the
sum of points. The data on index lesions are shown in
Table 1.
Table 1 – Criteria for calculating the index lesions of the internal organs of mice infected with tuberculosis.
Organ Index lesion
Liver Maximum: 5 points
No change: 0; increased: 1; increased: +1; focus: 3; many: 5
Spleen Maximum: 5 points
No change: 0; increased: 1–2; increased:+1; focus: 3; many: 5
Abdominal cavity Maximum: 5 points
No change: 0; focus single: 1; several foci: 2; joining foci: 4; general intestinal lesions: 5
Lungs Maximum: 5 points
No change: 0; full blooded: 1–2; single foci of caseous necrosis: 3; several foci: 4; joining foci: 5
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view in of the section (lungs, spleen, and liver) was carried
out, from which small pieces of size 0.3 cm  0.2 cm were
cut. The tissue taken was fixed by the use of 10% neutral for-
malin. Pieces were conducted by uplink concentrations of
alcohol, water was removed and covered with paraffin. Then,
the pieces were fixed in wooden blocks. The paraffin-
embedded pieces were used in the production of histological
sections on a microtome to a thickness of 4–6 lm. The sec-
tions were painted with hematoxylin and eosin stain using
van Gieson’s picrofuchsin method. The painted sections were
placed on a glass slide and fixed using polystyrene. Tissue
specimens were examined using a microscope (Olympus
BX41, Tokyo, Japan). The most demonstrative sections were
used for the production of color photographs.
The experiment was reviewed and approved by the ethical
and bioethical committee of Kharkiv National Medical
University in Ukraine. The work was conducted in accordance
with the requirements of the European Convention for the
Protection of Vertebrate Animals (Strasbourg, March 18,
1986) and the Directive of the Council of the European
Economic Society for the Protection of Vertebrate Animals
(Strasbourg, November 24, 1986).
Results
At the final stage of the experiment, all animals were removed
following the macroscopic study of the lesion character of the
internal organs with TB.
The study of macroscopic changes established the
following:Table 2 – Effect of isoniazid, streptomycin, and quercetin and po
tuberculosis in mice, points (M ±m).
Groups Index lesion
Liver Spleen Ab
1 0 0 0
2 3.33 ± 0.21 2.33 ± 0.21 1.
3 3.00 ± 0.36 1.66 ± 0.21 1.
4 2.50 ± 0.22* 1.50 ± 0.22* 0.
5 1.66 ± 0.21** 0.83 ± 0.3** 0.
* Discrepancy is significant (p < 0.05) when compared with Group 2.
** Discrepancy is significant (p < 0.05) when compared with Group 3.1. The macroscopic study of the internal organs of the intact
animals (Group 1) showed no pathological changes. The
results of the study are presented in Table 2.
2. In the second group of animals, the macroscopic picture of
the internal organs showed active TB and increased liver
caseous foci. TB tubercles were observed not only in the
lungs, but in other tissues as well. Most of animals tended
to joining foci, most foci, and the level of caseous necrosis
was higher than in the lungs of the animals belonging to
the third, fourth, and fifth groups, which received antibi-
otic therapy and/or QP treatment. The total index lesions
with TB composed (11.49 ± 0.22 points).
3. The total macroscopic lesion of the group that received QP
treatment (7.83 ± 0.22 points) was significantly lower
compared with that of the group that did not receive
treatment, and also was not significantly lower in
the group that received only ATP (8.65 ± 0.40 points). In
combinations of QP and ATP, we observed a significant
decrease in these indicators (4.59 ± 0.31 points) compared
with the group of animals that received only ATP treatment.
The following are the results of the microscopic study:
1. Group 1 (noninfected control mice) showed no specific
changes.
2. In the second control group of mice (infected with MBT
H37Rv), epithelioid cellular granulomas in the lungs, livers,
and spleens were macroscopically and microscopically
observed, and were found mostly with caseous necrosis
in the center (Fig. 1). The most striking changes were
found in the spleens, and to a lesser extent in the liverslyvinylpyrrolidone, and their combinations on experimental
dominal cavity Lungs Sum
0 0
50 ± 0.22 4.33 ± 0.21 11.49 ± 0.22
16 ± 0.16 2.83 ± 0.16 8.65 ± 0.40
50 ± 0.22* 3.33 ± 0.21* 7.83 ± 0.22*
50 ± 0.22** 1.66 ± 0.21** 4.59 ± 0.31**
Fig. 1 – Observation number 3, male, Group 2 (MBT H37Rv
infected). A typical epithelioid tubercle in the spleen with
caseous necrosis in the center (hematoxylin and eosin
stain, original magnification, 200).
Fig. 3 – Observation number 25, male, Group 4 (MBT
H37Rv infected and treated with quercetin and
polyvinylpyrrolidone). An epithelioid tubercle in the spleen
with distinct limiting area of connective tissue with
fibrotization in the center (hematoxylin and eosin stain,
original magnification, 200).
Fig. 4 – Observation number 2, male, Group 4 (MBT H37Rv
infected and treated with quercetin and
polyvinylpyrrolidone). An epithelioid tubercle in the spleen
with distinct limiting area of connective tissue with
fibrotization in the center (van Gieson’s stain, original
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of varying degrees in the livers and vascular full-blooded
in the spleens and lungs were detected.
3. In the third control group (infected mice) treated with ATP,
epithelioid cellular granulomas were detected, but to a les-
ser degree and were of smaller size, with caseous necrosis
in the center in 50% of the cases (Fig. 2). In the examined
organs, vascular full-blooded and fatty degeneration of
hepatocytes in the livers were found.
4. In the first experimental group (infected mice) treated with
QP, a small number of epithelioid cellular tubercles of
smaller size were observed, almost without caseous necro-
sis, including a limiting area of connective tissue in 50% of
the cases (Figs. 3 and 4). Giant multinucleate Langhans
cells and lymphocytes were found. Some epithelioid cellu-
lar tubercles were fibrotized.
5. The smallest number of tubercles was found in the second
experimental group (infected mice) treated with QP and
ATP. The microscopic investigation showed epithelioid cel-
lular tubercles without necrosis in the center, with an areaFig. 2 – Observation number 23, male, Group 3 (MBT
H37Rv infected and treated with antituberculosis
preparation). A typical epithelioid tubercle in the spleen
with caseous necrosis in the center (hematoxylin and eosin
stain, original magnification, 200).
Fig. 5 – Observation number 18, female, Group 5 (MBT H37Rv
infected and treated with antituberculosis preparation and
quercetin and polyvinylpyrrolidone). An epithelioid tubercle
in the spleen with distinct limiting area of connective tissue
with fibrotization in the center (hematoxylin and eosin
stain, original magnification, 200).
magnification, 200).
Fig. 6 – Observation number 6, female, Group 5 (MBT H37Rv
infected and treated with antituberculosis preparation and
quercetin and polyvinylpyrrolidone). An epithelioid tubercle
in the spleen with distinct limiting area of connective tissue
(van Gieson’s stain, original magnification, 200).
Fig. 7 – Observation number 6, female, Group 5 (MBT H37Rv
infected and treated with antituberculosis preparation and
quercetin and polyvinylpyrrolidone). An epithelioid tubercle
in the spleen with distinct limiting area of connective tissue
with giant multinucleate Langhans cell (hematoxylin and
eosin stain, original magnification, 400).
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with fibrotization in the center (Figs. 5 and 6). A large
number of giant multinucleate Langhans cells (Fig. 7) and
lymphocytes are observed. No fatty degeneration of
hepatocytes in the liver was found.
Conclusions
Under the influence of QP, the separation of caseous necrosis
of granulomas from unaffected areas begins through connec-
tive tissue with fibrotization in the central part and a large
number of Langhans cells and lymphocytes that are not
observed in the control groups. The interaction of QP with
anti-TB drugs shows more obvious effects: fast tendency of
epithelioid cellular tubercles to fibrotization and separation
of TB granulomas through connective tissue. In addition, in
the control groups of animals infected with TB, in contrast
to the experimental groups, fatty degeneration of hepatocytes
is observed. Thus, we have shown the hepatoprotective func-
tion of QP against TB.Conflicts of interest
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